Bavarian Nordic upgrades guidance following vaccine contract

Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.

Photo: Philip Davali/Ritzau Scanpix

A smaller outbreak of monkeypox is being documented across the world, as several countries, including the US and some in Europe, have continued to report new cases of the viral infection.

A few different names have come up repeatedly in these reports – Jynneos, Imvanex, and Imvamune – depending on where one is located in the world. They all refer back to the same thing: the only approved monkeypox vaccine in the world, which has been developed by Danish biotech firm Bavarian Nordic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs